AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01497236 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Supplement: Nutrition supplement with RUTF or MNP
Description: 14 days nutritional supplementation with either~* a fortified high quality food(RUTF), 1 sachet/day, 500 kcal and multi micronutrients~* a multi micronutrient powder (MNP), 2 sachets per day, no calories, twice recommended daily intake~* a placebo (to MNP), 2 sachets per day , no calories, no micronutrients, containing micronutrient carrier
Study NCT00938652 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine/carboplatin
Description: Gemcitabine 1000 mg/m2 intravenous infusion (30 ± 10 minutes)~Carboplatin AUC 2 intravenous infusion (30 ± 10 minutes or 60 ± 10 minutes)
Study NCT00938652 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine/carboplatin
Description: Gemcitabine 1000 mg/m2 intravenous infusion (30 ± 10 minutes)~Carboplatin AUC 2 intravenous infusion (30 ± 10 minutes or 60 ± 10 minutes)
Study NCT00938652 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iniparib
Description: Body weight adjusted dose~intravenous infusion (60 ± 10 minutes)
Study NCT02076477 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: concurrent chemoradiotherapy
Description: Radiation（image-guided radiotherapy）：（1）primary tumors≤3cm，Hypofractionated radiation therapy，accumulated dose BED ≥80Gy （central lung cancer），BED ≥100Gy（Peripheral lung cancer）.（2）primary tumors>3cm，conventional fractionated radiotherapy，accumulated dose BED=60-66Gy/30-33f.（3） regional lymph node:conventional fractionated radiotherapy，accumulated dose BED=60-66Gy/30-33f.（4） Brain metastases： whole brain radiation therapy，36Gy/12f,Intracranial metastases，48Gy/12f.（5） bone metastasis：36 Gy/12f.
Study NCT02076477 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: concurrent chemoradiotherapy
Description: Radiation（image-guided radiotherapy）：（1）primary tumors≤3cm，Hypofractionated radiation therapy，accumulated dose BED ≥80Gy （central lung cancer），BED ≥100Gy（Peripheral lung cancer）.（2）primary tumors>3cm，conventional fractionated radiotherapy，accumulated dose BED=60-66Gy/30-33f.（3） regional lymph node:conventional fractionated radiotherapy，accumulated dose BED=60-66Gy/30-33f.（4） Brain metastases： whole brain radiation therapy，36Gy/12f,Intracranial metastases，48Gy/12f.（5） bone metastasis：36 Gy/12f.
Study NCT02076477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel:60mg/m2 d1,Given IV
Study NCT02076477 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel:60mg/m2 d1,Given IV
Study NCT02076477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: pemetrexed: 500mg/m2 d1,Given IV
Study NCT02076477 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pemetrexed
Description: pemetrexed: 500mg/m2 d1,Given IV
Study NCT02076477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin：25mg/m2 d1-3，Given IV
Study NCT02076477 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin：25mg/m2 d1-3，Given IV
Study NCT02710292 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Delefilcon A contact lenses
Study NCT02710292 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Narafilcon A contact lenses
Study NCT04803448 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Benefit statement
Description: The participant reads this statement after asked one of eight health questions~1. What is your height in inches?~2. What is your weight in pounds?~3. How many days out of the last 2 weeks did you drink alcohol?~4. How often a month do you use other substance such as marijuana, cocaine, ecstasy, or other drugs~5. How often a month do you use Rx or non-Rx medications to excessive amounts?~6. When was the last time you smoked a cigarette?~7. How many days in the last 2 weeks did you engage in more than 30 min exercise?~8. How many times did you engage in sexual activity in the last month with another individual? . The statement reads: Accurately answering this will increase the likelihood of a correct diagnosis.~An example of this with one of the 8 health questions is... What number of days in the last 2 weeks you engaged in >30 minutes of exercise? Accurately answering this will increase the likelihood of a correct diagnosis.
Study NCT04803448 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Risk Statement
Description: The participant reads this statement after being asked one of eight health questions.~The statement reads: Inaccurately answering this will increase the likelihood of an incorrect diagnosis.
Study NCT04803448 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Privacy Statement
Description: The participant reads this statement after being asked one of eight health question for example. We will not share or sell this personal health information with anyone. We will comply with all HIPPA regulations regarding the protection of your data.
Study NCT04803448 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Benefit + Privacy
Description: The statement reads Accurately answering this will increase the likelihood of a correct diagnosis. We will not share or sell this personal health information with anyone. We will comply with all HIPPA regulations regarding the protection of your data.
Study NCT04803448 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Risk + Privacy
Description: The statement reads Inaccurately answering this will increase the likelihood of an incorrect diagnosis. We will not share or sell this personal health information with anyone. We will comply with all HIPPA regulations regarding the protection of your data.
Study NCT02803125 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychosocial intervention
Description: This intervention is to be developed during the study. It will likely include modules that provide anger management strategies, communication skills, and education about interpersonal relationships and social support. In addition, psychoeducation about behavioral activation and stress management will likely be included
Study NCT02803125 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Support group control
Description: The support groups will be process-oriented in nature with core elements manualized to facilitate consistency of the intervention. In particular, group leaders will facilitate a check-in with the group, and the agenda will be open to topics brought in by group members
Study NCT01746043 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Armodafinil
Description: 150 mg by mouth once a day for 6 weeks.
Study NCT01746043 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 1 capsule by mouth 2 times a day for 6 weeks.
Study NCT01746043 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 capsule by mouth 2 times a day for 6 weeks.
Study NCT01746043 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: 100 mg by mouth 2 times a day for 6 weeks.
Study NCT01746043 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Completion of symptom questionnaires before chemoradiation and then 1 time a week during Weeks 1-10 of the study. Questionnaire take up to 5 minutes to complete.
Study NCT01746043 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaires
Description: Completion of symptom questionnaires before chemoradiation and then 1 time a week during Weeks 1-10 of the study. Questionnaire take up to 5 minutes to complete.
Study NCT04372628 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lopinavir/Ritonavir 400 mg/100 mg
Description: Lopinavir/Ritonavir tablets
Study NCT04372628 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Unmatched placebo
Study NCT01903421 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spinal anesthesia group: bupivacaine 10-15mg
Study NCT01903421 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: General anesthesia group: induction propofol 1.5-2mg/kg and fentanyl 1-3g/kg, maintained with isoflurane or sevoflurane
Study NCT01903421 — intervention group
Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: Blood test
Description: DNA will be tested for the presence of ε4 allele of the apolipoprotein E gene
Study NCT01903421 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lumbar spinal tap
Description: 1ml of cerebrospinal fluid (CSF) removed and stored for further analysis of amyloid tau protein after completion of the study
Study NCT00206687 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Spheramine (BAY86-5280)
Description: Bilateral implantation of Spheramine into the postcommissural putamen, each side at a dose of 325,000 cells
Study NCT01903421 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Montreal Cognitive Assessment (MOCA) and MMSE
Study NCT01037439 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Adaptive Servo-controlled Ventilation (ASV)
Description: Pressure support ventilation adapts to meet a target ventilation level that is constantly being assessed
Study NCT01037439 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adaptive Servo-controlled Ventilation (ASV)
Description: Pressure support ventilation adapts to meet a target ventilation level that is constantly being assessed
Study NCT04416893 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: RT-PCR SARS-Cov2
Description: nasopharyngeal swab will be taken for detection of SARS-CoV-2 by RT-PCR
Study NCT04416893 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Sars-Cov2 serology
Description: A microsample of blood will be taken for serology
Study NCT02288754 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood test
Description: No intervention except to collect blood for diagnostic test development
Study NCT02062359 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-NY ESO-1 T cell receptor (TCR) cluster of differentiation 62L (CD62L)+ cells
Description: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-NY ESO-1 T cell receptor (TCR) CD62L+ cells and high dose aldesleukin.~On day 0, cells (1x10e9 to 2x10e11) will be infused intravenously on the Patient Care Unit over 20-30 minutes.
Study NCT02062359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Aldesleukin 720,000 IU/kg intravenous (IV) (based on total body weight) over 15 minutes approximately every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).
Study NCT02062359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: On days -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml dextrose 5% in water (D5W) with Mesna 15 mg/kg/day X 2 days over 1 hr.
Study NCT02062359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: On days -5 to -1: Fludarabine 25 mg/m(2)/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days.
Study NCT03128424 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PQ Bypass Stent Graft System
Description: The PQ Bypass™ Stent Graft System is indicated to improve luminal diameter in the treatment of patients with symptomatic de novo or restenotic native lesions or occlusions of the superficial femoral artery (SFA) and/or proximal popliteal artery, with reference vessel diameters of 5.0 to 6.7 mm and lesion lengths up to 180 mm.
Study NCT00214305 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Range of Motion Therapy Program
Description: The program involves exercises and maneuvers that include voluntary maximal movements of the tongue, pitch range exercises, head lifting (Shaker exercise), resistance to laryngeal excursion (Mendelsohn Maneuver), breath holding after swallow and cough, thermal-tactile stimulation (ice), suck-swallow, optimal posturing, and dietary changes.
Study NCT00214305 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Postural Sensory Therapy Program
Description: The program involves all of the above, except that range of motion exercises (voluntary maximal movements of the tongue, pitch range exercises, head lifting, resistance to laryngeal excursion, breath holding after swallow and cough) are not performed.
Study NCT04279314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trofinetide
Description: Trofinetide solution of 30-60 mL based on subject's weight at Baseline, administered twice daily by mouth or gastrostomy tube (G-tube)
Study NCT03026218 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GlucoseMama application with blood sugar monitoring and carb monitoring.
Description: We will use the Glucosemama application to review glucose and carb logs on a weekly basis. This will be reviewed with the patient in order to adjust dietary and medicals.
Study NCT03026218 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group prenatal care for GDM.
Description: group prenatal care is a group based intervention where individuals with GDM will meet together to learn about pregnancy and diabetes.
Study NCT03026218 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Group prenatal care for GDM.
Description: group prenatal care is a group based intervention where individuals with GDM will meet together to learn about pregnancy and diabetes.
Study NCT04189354 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (t-DCS) device
Description: t-DCS is a brain electrostimulation technique that consists of applying a current of low intensity (between 1 and 2 mA) on the scalp via two electrodes, in order to modify the cerebral activity of the stimulated zones. The investigators use the Soterix Medical t-DCS devices of the mini-CT 1x1 type.
Study NCT04189354 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial direct current stimulation (t-DCS) device
Description: t-DCS is a brain electrostimulation technique that consists of applying a current of low intensity (between 1 and 2 mA) on the scalp via two electrodes, in order to modify the cerebral activity of the stimulated zones. The investigators use the Soterix Medical t-DCS devices of the mini-CT 1x1 type.
Study NCT02546934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABX, cisplatin
Description: ABX 125 mg/m2, IV drip 30 minutes, D1, D8 Cisplatin 75 mg/m2, IV drip 120 minutes, D1
Study NCT02546934 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine, Cisplatin
Description: Gemcitabine 1250 mg/m2, IV drip 30 minutes, D1, D8 Cisplatin 75 mg/m2, IV drip 120 minutes, D1
Study NCT03611153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4831 Oral Myeloperoxidase Inhibitor
Description: A single administration dose of 30 mg oral MPO inhibitor given orally following baseline, resting and exercise testing in patients during right heart catheterization.
Study NCT03611153 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: A single administration dose of 30 mg placebo given orally following baseline, resting and exercise testing in patients during right heart catheterization.
Study NCT03664505 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Compression garment (manual)
Description: Garment based on manual measurement
Study NCT03664505 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Compression garment (scan)
Description: Garment based on scan measurement
Study NCT01964326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin calcium 10 mg
Description: Atorvastatin calcium 10 mg tablet to be administered orally every day
Study NCT00790452 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: 325 mg daily by mouth
Study NCT00790452 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet daily by mouth
Study NCT01239667 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individual oriented planning of the rehabilitation program for patients with heart failure
Description: Individual oriented rehabilitation plan in collaboration with the patient followed by measuring health related quality of life and self care behavior
Study NCT04188379 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: efgartigimod
Description: Intravenous infusion of efgartigimod
Study NCT04188379 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous infusion of placebo
Study NCT01089322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inhaled corticosteroid plus LABA plus oral corticosteroid
Description: formoterol plus budesonide 12/400mcg 2times/day and 6/200 mcg as needed and prednisone 40 mcg
Study NCT03166150 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multi-modal rehabilitation program
Description: Patients will receive 12 weeks of exercises.
Study NCT03166150 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic Floor Physical therapy
Description: Pelvic Floor Physical therapy
Study NCT02582346 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI acquisition - no contrast agent
Description: No surgery. Volunteers will have an MRI with a 3T clinical system. Installation will be performed according to standard protocols. Different neurography and tractography sequences will be acquired in order to get different contrasts.
Study NCT04082884 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Very Low Carbohydrate Diet
Description: A very low carbohydrate diet (VLCD), is defined as limiting carbohydrate intake to 11% of total daily caloric intake.
Study NCT00206687 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: Sham surgery procedure without penetration of the dura mater. Nothing wil be implanted into the brain.
Study NCT04131270 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Planning + Education
Description: Planning: Participants will fill in the planning forms that efer to replacing sedentary behavior with physical activity.~The following behavior change techniques are included in the planning intervention protocol: action planning, barrier identification, prompting self-talk, relapse prevention/coping planning. Applications of all behavior change techniques would include references to planning.
Study NCT04131270 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: The education would include extended sedentary behavior and physical activity education, delivered face-to-face by the experimenters. The education includes: (1) the behavioral guidelines, tailored to age and health status of the participants, (2) the examples of exercises and their metabolic equivalent, and (3) the education about ways to break sedentary behavior with active breaks.
Study NCT04131270 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: The education would include extended sedentary behavior and physical activity education, delivered face-to-face by the experimenters. The education includes: (1) the behavioral guidelines, tailored to age and health status of the participants, (2) the examples of exercises and their metabolic equivalent, and (3) the education about ways to break sedentary behavior with active breaks.
Study NCT02427659 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Virtual Reality Distraction
Description: The subjects will receive a 20-minute Virtual Reality Distraction (VRD) during their wound care procedure. The nurse will be doing their wound care.
Study NCT02427659 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Audio (sound of nature)
Description: The subjects will listen to an audio recording called Sounds of Nature during their wound care.
Study NCT02427659 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control standard nurse wound care
Description: The subjects will receive their standard care during wound care. The nurse will be doing the wound care.
Study NCT01007656 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: GD Antrodia camphorata
Description: Three 500mg capsules per oral dose, twice daily with an interval of 12 hours for 90 days
Study NCT00337272 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo taken 30 minutes before bedtime days 1-28 of treatment period
Study NCT00337272 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramelteon
Description: 8 mgs daily for days 1-28 of treatment period
Study NCT05008952 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High-fat shake
Description: All participants will be given a high-fat test meal to examine their postprandial triglyceride response.
Study NCT05008952 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-fat shake
Description: All participants will be given a high-fat test meal to examine their postprandial triglyceride response.
Study NCT00659490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1940
Description: 800ug oral administration
Study NCT00659490 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen
Description: 500mg oral administration
Study NCT00659490 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo given pre-surgery
Study NCT02341508 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg Lpathomab